Scott Whitson

Prions, and What Finally Changed in 2026

Last updated: November 2026

My father died of Creutzfeldt-Jakob disease. The personal part of this is here.

What follows is what the research looks like now.

What a prion is

Most infectious diseases have a genome. A bacterium, a virus, a fungus - each carries instructions for making more of itself. A prion does not. It is a misfolded version of a protein the body already makes, called PrP (prion protein). The normal protein, PrPC, sits on the surface of neurons, largely folded into helices. The disease form, PrPSc, is mostly beta sheet. When PrPSc touches PrPC, it templates it into the misfolded shape. The new copy then does the same thing to the next one.

That is the whole mechanism. No nucleic acid, no replication machinery, just a shape that propagates. Stanley Prusiner proposed it in 1982 and it earned him the 1997 Nobel Prize in Physiology or Medicine, and it remains one of the stranger facts in biology: a protein that is infectious by conformation alone.

PrPSc does not get cleared the way ordinary misfolded proteins do. It is resistant to proteases, it accumulates, and the neurons around it die. The brain becomes spongy; that is the "spongiform" in transmissible spongiform encephalopathy. Once symptoms start, the decline is usually measured in months, not years. For sporadic CJD, the most common form, death typically comes within four months to two years of onset.

The human forms, and the numbers

  • Sporadic CJD (sCJD) - about 85% of cases. No known trigger; the protein misfolds on its own. Roughly 1–2 cases per million people per year.
  • Genetic prion disease - about 10–15%. An inherited mutation in PRNP, the gene for PrP. It includes familial CJD, Gerstmann-Sträussler-Scheinker disease, and fatal familial insomnia.
  • Acquired - the rarest. Kuru, from ritual transmission; iatrogenic cases from contaminated surgical instruments or grafts; and variant CJD (vCJD), from eating beef contaminated with bovine spongiform encephalopathy.

The same protein misfolds in animals: scrapie in sheep and goats, BSE in cattle, and chronic wasting disease (CWD) in deer, elk, and moose. CWD is the one spreading fastest, and it is now present across much of North America. Prions shed into soil by infected animals stay infectious for years.

Why the field had nothing

For decades, prion disease looked untreatable for structural reasons, not just of effort. The infectious agent has no enzymes to inhibit, no genome to interfere with, no metabolism to poison. It is your own protein, folded wrong. There was nothing to attack that wasn't also you.

The other problem is timing. By the time symptoms appear, substantial neuronal loss has already happened. Anything that only slows the process is starting from a deep deficit.

PrP itself is now the target

The pivot is a single observation that turned out to be decisive. Mice with the Prnp gene knocked out do not get prion disease. If the body does not make the normal protein, the misfolded form has nothing to convert. PrP is the substrate of the entire process.

That makes PrP itself a drug target. Lower the amount of PrP the brain produces, and you starve the reaction. Everything in the clinic right now is a variation on that idea.

A first-in-human drug

In April 2026, the Broad Institute announced the first human trial of PrP-siRNA, a new drug designed to lower PrP. The trial is called PRiSM, and the drug is PrP-siRNA, a "divalent" small interfering RNA, meaning two siRNA molecules linked together so they distribute more widely through brain tissue. It is delivered by intrathecal injection, a lumbar puncture, because it cannot cross the blood-brain barrier on its own.

Inside the cell, the siRNA finds the RNA instructions for PrP and cuts them, so less protein gets made. In mice, a version of it lowered brain PrP to 49% of normal levels, and a single dose given after symptoms began increased survival time by 64%.

The trial is small: about 45 participants, including some people at genetic risk who do not yet have symptoms, enrolling one dose level at a time, escalating from 50 to 100 to 200 milligrams, each participant receiving a single dose. There is no placebo arm. Instead, when enrollment pauses between dose levels, patients who would have been screened are offered a parallel observational arm, so there is still a comparison group without giving anyone a placebo.

The investigators, Sonia Vallabh and Eric Minikel, are wife and husband. Vallabh learned in 2011 that she carries the genetic mutation that causes prion disease; she and Minikel changed careers to work on it. They have published their entire Investigational New Drug filing publicly, which is not how drug development is normally done.

What they say about their own trial is worth repeating plainly: most drugs that enter clinical trials fail, the first drug is usually not a cure, and there is no human data yet to suggest this one helps anyone. If it works at all, the mouse data suggest it slows further progression. It does not halt the disease and does not reverse damage already done.

The rest of the pipeline

PRiSM is not alone.

  • ION717 (Ionis Pharmaceuticals), an antisense oligonucleotide, same lower-the-protein idea, delivered intrathecally. Its Phase 1/2a trial, PrProfile, began in January 2024 - the first PrP-lowering drug tested in people - and has finished enrolling.
  • ALN-6457 (Regeneron), another RNA-based PrP-lowering candidate, entering a Phase 1/2 trial for symptomatic prion disease.
  • CHARM, a CRISPR-based epigenetic silencing approach, also from the Vallabh/Minikel group, aimed at turning the gene down without cutting it.
  • Efavirenz, an old HIV drug, now in a randomized, placebo-controlled trial in China for CJD. A repurposing attempt, still recruiting.

Open ideas for stopping the spread

Lowering production via PrP supply is one lever. Other approaches are also actively researched:

Block the conversion machinery

  • NGI-1 - inhibits the oligosaccharyltransferase (OST) complex, which attaches sugar chains to PrP. Published in PLOS Pathogens in January 2026. The striking result: it works against both mouse and hamster prion strains, and against human sCJD prions in lab-grown cerebral organoids. Strain specificity has been the field's recurring wall: most compounds work on one prion strain and not others. This one, so far, crosses strains.
  • Kifunensine - an older glycosylation inhibitor, but strain-specific, which is the limitation NGI-1 was built to get past.

Enhance the cell's own cleanup

  • Elacridar - concentrates in lysosomes, boosts their activity, and activates autophagy. It enhanced degradation of newly formed PrPSc and permanently cured one prion-infected cell line. It also blocked the seeding activity of alpha-synuclein and tau prions, which matters far beyond prion disease: those are the proteins involved in Parkinson's and Alzheimer's. Elacridar is already in human trials for cancer, which makes it a serious repurposing candidate.
  • Autophagy, more broadly: the cell's recycling system, and whether it can be dialed up to clear PrPSc faster than it forms.

Small molecules that interfere directly

  • GT863 (PE859) - a curcumin derivative that inhibits abnormal PrP formation and is effective when given orally in mice.
  • BMD42-2910 - a benzoxazole derivative that prolongs survival in an animal model.
  • Uroporphyrin I - reported to inhibit prion propagation in a way that is both strain- and species-independent, which is the property everyone wants.
  • Zn(II)-BnPyP - a compound that both degrades PrPC and blocks its conversion. Two mechanisms in one molecule.
  • IND24, IND81, and Anle138b - oral compounds that lengthen incubation time in mice, and also the clearest cautionary story in the field, because prions evolve resistance to them.

Immunotherapy and vaccination

  • A CWD vaccine, published in PLOS Pathogens in April 2026, reduced or even prevented shedding of prions in the feces and urine of infected mice engineered to carry deer prion protein. It is the first demonstration that prion shedding can be blocked at all. For CWD, cutting shedding means cutting the environmental reservoir that drives transmission through a herd. It does not treat the individual animal, but at population scale that may matter more.

Diagnose earlier

This is not a treatment, but it may be the bottleneck.

  • RT-QuIC (real-time quaking-induced conversion) detects the seeding activity of minute amounts of PrPSc, and has become standard for CJD diagnosis from cerebrospinal fluid.
  • Detection in blood and even tear fluid is advancing. In 2026 there were results on detecting CWD prions in the blood of healthy-appearing deer, and on improving RT-QuIC sensitivity in human CSF and tears.

The problems that remain

  • Strains. Prions are not one thing. The same protein misfolds into different conformations, and each conformation is a distinct strain with different behavior. A compound that cures one may do nothing for another. This is why NGI-1's strain-independence stands out.
  • Resistance. Prions replicate and mutate like any evolving population. Under sustained treatment with a single compound, resistant conformers emerge. Even combination therapy has produced prions resistant to both drugs. Prion treatment is going to look more like HIV or TB treatment than like a one-time cure.
  • Delivery. The blood-brain barrier keeps most drugs out. That is why the leading approaches are injected into the spine, and why the small-molecule and lysosomal routes matter: they are the ones that might become a pill.
  • Timing. The disease is usually diagnosed after significant damage. Slowing a process that is already far along buys time but does not give it back.
  • PrP's normal job. We do not fully know what PrPC does. Suppressing it for years in a human is untested territory. Knockout mice are mostly fine, which is reassuring, but "mostly fine in mice" is not "fine in a person for a decade."
  • Economics. A disease affecting one to two people per million per year is not a market that drug companies chase. That is why the leading programs are nonprofit, academic, and publicly funded. The openness of the Vallabh/Minikel group is both admirable and important for the whole field.

For most of my life, CJD was a diagnosis with no next step. You learned the name, you learned there was nothing to be done, and that was the end of the conversation. My father's illness went the way the textbooks describe, because there was no other way for it to go.

What is different now is not that there is a cure. There isn't. What is different is that there is a target, a mechanism worth attacking, and drugs in people. The first ones will likely fail or disappoint. But the field has moved from "this is untreatable in principle" to "this is hard, and we are trying, and we know what we are trying."

Sources